Cal 1

Drug Profile

Cal 1

Alternative Names: Autologous CD34+ Haematopoietic Stem/Progenitor Cells + CD4+ T Lymphocytes Transduced with LVsh5/C46 - Calimmune; Cal 1 therapy; Cal 1-modified HSPC; Cal 1-transduced haematopoietic stem progenitor cells; Cal-1; Dual Anti-HIV Gene Transfer Construct; LVsh5C46; LVsh5C46-transduced-HSPC

Latest Information Update: 16 Aug 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Calimmune
  • Class Antivirals; Cell therapies; Gene therapies
  • Mechanism of Action Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II HIV-1 infections

Most Recent Events

  • 20 Jul 2018 CSL Behring plans the GENHIV phase I/II trial for HIV-1 Infections in France (NCT03593187)
  • 01 Nov 2017 Calimmune completes a phase I/II trial in HIV-1 infections in USA (NCT01734850)
  • 13 Sep 2017 Calimmune withdraws a phase I/II trial prior to enrolment due to participant recruitment difficulties for HIV-1 infections in Australia and USA (ACTRN12615000763549)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top